Protalix BioTherapeutics (NYSEMKT:PLX) just reported results for the second quarter of 2024.
- Protalix BioTherapeutics reported earnings per share of -3 cents. This was below the analyst estimate for EPS of 2 cents.
- The company reported revenue of $13.47 million.
- This was 7.79% better than the analyst estimate for revenue of $12.50 million.